コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ulous meningitis, and two as not tuberculous meningitis.
2 s on healthcare-associated ventriculitis and meningitis.
3 MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis.
4 se is untested in patients with cryptococcal meningitis.
5 ed to establish nonhematogenous pneumococcal meningitis.
6 al invasive infections, including sepsis and meningitis.
7 re aggressive treatment than anthrax without meningitis.
8 iagnostic and prognostic factors for anthrax meningitis.
9 umococcus) is the primary cause of bacterial meningitis.
10 T) status for people with a first episode of meningitis.
11 rough the BBB into the brain to cause lethal meningitis.
12 isease severity and outcome in patients with meningitis.
13 tocida is a rare cause of neonatal bacterial meningitis.
14 the blood brain barrier, causing cause fatal meningitis.
15 gens responsible for most cases of bacterial meningitis.
16 s comprising 373 patients with meningococcal meningitis.
17 most frequent and critical type of bacterial meningitis.
18 re more frequently associated with sepsis or meningitis.
19 nfluence the pathophysiology of pneumococcal meningitis.
20 is the second most common cause of neonatal meningitis.
21 with morbidity and mortality of pneumococcal meningitis.
22 GBS) is a major cause of neonatal sepsis and meningitis.
23 ring function in a rat model of pneumococcal meningitis.
24 -1 has the potential to prevent pneumococcal meningitis.
25 GBS infection include sepsis, pneumonia, and meningitis.
26 ents (5.5%) had a suspected ventriculitis or meningitis.
27 o apply to meningococcal meningitis or viral meningitis.
28 ile sites to cause bloodstream infection and meningitis.
29 years with symptoms and signs suggestive of meningitis.
30 confer protection against cardiac damage and meningitis.
31 a for 325 children hospitalized with E. coli meningitis.
32 ens from patients and mice with pneumococcal meningitis.
33 lood-brain barrier during the development of meningitis.
34 al effect on confirmed group A meningococcal meningitis.
35 o are developing and dying from cryptococcal meningitis.
36 isms of CNS entry as well as the severity of meningitis.
37 in the early host response during bacterial meningitis.
38 as 50% (7 of 14) with 1:160-1:320 titers had meningitis.
39 ological diseases including encephalitis and meningitis.
40 al diagnostic test for suspected tuberculous meningitis.
41 ed as significant risk factors for bacterial meningitis.
42 percentage of infants with NDI following GBS meningitis.
43 s initial diagnostic testing for tuberculous meningitis.
44 cipients), one case of Haemophilus influenza meningitis (1% rabies-vaccine recipients), and one case
46 nisters of health declared the prevention of meningitis a high priority and asked the World Health Or
47 us pneumoniae is the main cause of bacterial meningitis, a life-threating disease with a high case fa
48 mmon pathogens accounting for most bacterial meningitis, a serious global infectious disease with hig
49 rubii is the causative agent of cryptococcal meningitis, a significant source of mortality in immunoc
54 elop healthcare-associated ventriculitis and meningitis after the following procedures or situations:
56 with healthcare-associated ventriculitis and meningitis (American Academy of Neurology, American Asso
57 ight into the seasonal dynamics of bacterial meningitis and add to knowledge about the global epidemi
59 r of morbidity and mortality of pneumococcal meningitis and also suggests a potential role for MIF as
60 a foodborne pathogen that causes septicemia, meningitis and chorioamnionitis and is associated with h
61 Rapid diagnosis and treatment of infectious meningitis and encephalitis are critical to minimize mor
63 sts for the most common causes of infectious meningitis and encephalitis have the potential for high
65 es that are transmitted by insects and cause meningitis and encephalitis in subsets of individuals in
71 ial reductions in the incidence of suspected meningitis and epidemic risk, and a substantial effect o
72 ide cohort of 405 patients with pneumococcal meningitis and in 329 controls matched for age, gender,
74 ynx and the causative agent of meningococcal meningitis and meningococcemia, is capable of invading a
75 neumococcus) is a leading cause of bacterial meningitis and neurological sequelae in children worldwi
77 r example, tuberculosis, syphilis, bacterial meningitis and sepsis), fungal (for example, cryptococca
81 o knowledge about the global epidemiology of meningitis and the host, environment, and pathogen chara
83 osuppression who developed recurrent aseptic meningitis and underwent brain biopsy revealing a diagno
84 th strains, oral infection resulted in focal meningitis and ventriculitis with recruitment of inflamm
85 ng patients with HIV-associated cryptococcal meningitis and was associated with more adverse events a
86 d sepsis), fungal (for example, cryptococcal meningitis) and parasitic (for example, malaria, neurocy
87 ents (5.5%) had a confirmed ventriculitis or meningitis, and 15 patients (5.5%) had a suspected ventr
88 nted with pneumonia, 78 (35%) presented with meningitis, and 16 (7%) had other clinical conditions.
92 need for inotropes, mechanical ventilation, meningitis, and death, was unchanged after introduction
93 on in pregnant women, as well as septicemia, meningitis, and gastroenteritis, primarily in immunocomp
94 humanized mice was characterized by gliosis, meningitis, and meningoencephalitis, and glial cells wer
95 . coli K1 is a novel pathogenic mechanism in meningitis, and pharmacological upregulation of PPAR-gam
96 3 that caused meningitis, septicemia without meningitis, and septicemia with meningitis, respectively
98 onths after discharge with symptoms of acute meningitis, and was found to have Ebola virus in cerebro
99 ines for epidemic diseases, such as cholera, meningitis, and yellow fever, have become common over th
102 viding new insights into the pathogenesis of meningitis-associated hearing loss that reveal new start
103 ion of West Africa has the highest bacterial meningitis attack and case fatality rate in the world.
104 surveillance data for nine countries in the meningitis belt (Benin, Burkina Faso, Chad, Cote d'Ivoir
105 A meningococcal vaccine, PsA-TT, in Africa's meningitis belt countries represented the first introduc
107 ia meningitidis serogroup A epidemics in the meningitis belt of sub-Saharan Africa, a meningococcal s
108 ng mass vaccination campaigns in the African meningitis belt with group A meningococcal conjugate vac
109 conjugate vaccine developed for the African meningitis belt, an enhanced meningitis surveillance net
114 ant determinant of mortality in cryptococcal meningitis, but its use in aiding clinical decision maki
115 ons were consistent with chronic lymphocytic meningitis, but no definitive cause was identified.
116 ay contribute to susceptibility of bacterial meningitis, but which genes contribute to the susceptibi
118 assified as probable or definite tuberculous meningitis by uniform case definition, excluding Xpert U
120 study in 469 community-acquired pneumococcal meningitis cases and 2072 population-based controls from
121 From Jan 1 to June 30, 2015, 9367 suspected meningitis cases and 549 deaths were reported in Niger.
123 ounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95% CI 113 600-
125 ters >1:640, 96% (27 of 28) had cryptococcal meningitis (cerebrospinal fluid CRAG-positive) whereas 5
128 eficiency virus/AIDS-associated cryptococcal meningitis (CM) frequently experience clinical deteriora
132 rmine the national incidence of cryptococcal meningitis (CM), and describe characteristics of cases d
134 cases) for probable or definite tuberculous meningitis compared with 43% (23-66; 10/23) for Xpert an
136 e understanding of global seasonal trends in meningitis could be used to design more effective preven
138 temporal manner may indicate early bacterial meningitis development in neurosurgical patients, enabli
141 en by participants with CSF WCC <5/microL at meningitis diagnosis: 28% (10/36) of such persons in the
142 uid data from all 37 laboratories performing meningitis diagnostics in Botswana were collected from t
143 umber of severe pathologies, such as aseptic meningitis, dilated cardiomyopathy, type I diabetes, par
146 d assessment tool for screening patients for meningitis during an anthrax mass casualty incident.
149 vely assess the performance of the FilmArray meningitis/encephalitis panel compared to conventional m
151 de vaccines had been used to control African meningitis epidemics for >30 years but with little or mo
155 infect the central nervous system and cause meningitis following the natural route of infection in m
157 nsible for 67.3% of 55 cases of eosinophilic meningitis from a cohort of 1,690 adult patients with CN
166 roup B (MnB) is a leading cause of bacterial meningitis; however, MnB is most commonly associated wit
167 occus (GBS) is the leading cause of neonatal meningitis; however, the molecular mechanisms that regul
171 med to describe features of Escherichia coli meningitis in a large population of children and the mol
172 Cryptococcus is the most common cause of meningitis in adults living with HIV in sub-Saharan Afri
177 several decades, the incidence of bacterial meningitis in children has decreased but there remains a
182 lous meningitis (TBM) is a frequent cause of meningitis in individuals with human immunodeficiency vi
185 the progression and outcome of pneumococcal meningitis in Rag1(-/-) mice lacking functional B and T
186 mortality among patients with other forms of meningitis in some populations, but their use is unteste
187 acteristics of nontyphoidal Salmonella (NTS) meningitis in South Africa, where human immunodeficiency
188 accounting for 33%-63% of all cases of adult meningitis in sub-Saharan Africa and >500 000 deaths ann
191 igns at presentation independently predicted meningitis in the derivation cohort and were tested as a
192 can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemi
193 ngitidis has been a major cause of bacterial meningitis in the sub-Saharan region of Africa in the me
194 lt patients with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia, Laos, Uganda
195 enAfriVac), in 2010, we analyzed the data on meningitis incidence and case fatality from countries re
196 nnual age-specific admission rates for viral meningitis, including specific viral aetiologies, in chi
202 ical features alone cannot determine whether meningitis is present and analysis of cerebrospinal flui
206 sing home, recent surgery, septic shock, NF, meningitis, isolated bacteremia, pneumonia, emm type 1 o
207 nd for patients with endocarditis, bacterial meningitis, lymphoma/leukemia, HIV/AIDS, internal organ
210 er as cases of encephalopathy, encephalitis, meningitis, myelitis, and seizures have also been report
211 ty presented with septicemia (n = 63 [49%]), meningitis (n = 16 [12%]) or both (n = 21 [16%]); howeve
212 e occurrence of serious infection (sepsis or meningitis), necrotizing enterocolitis, or mortality dur
213 ission had a sensitivity for finding anthrax meningitis of 89% (83%) in the adult (pediatric) validat
215 All 18 studies followed up survivors of GBS meningitis; only 5 of these studies also followed up sur
217 ement decisions, and outcomes of adults with meningitis or encephalitis in the United States (US) are
221 symptoms, clinical presentation of suspected meningitis or pneumonia, and evidence of radiographic pn
223 pneumococcal (n = 553), or viral (n = 1,433) meningitis or with herpes simplex encephalitis (n = 115)
224 R = 8.3; CI, 4.9-13.9; P < .0001), bacterial meningitis (OR = 3.8; CI, 1.2-12.0; P = .023), fungal me
225 s (OR = 3.8; CI, 1.2-12.0; P = .023), fungal meningitis (OR = 59.1; CI, 14.1-247.8; P < .0001), inter
227 the Ebola outbreak response and measles and meningitis outbreaks; and strengthening the integrated d
228 py in immunocompromised patients with herpes meningitis (P < .05), but not in the 27 patient-episodes
230 brospinal fluid (CSF) samples from suspected meningitis patients of all ages were examined by traditi
231 ity pension in former meningococcal or viral meningitis patients versus members of the comparison coh
233 loss is an important sequela of pneumococcal meningitis (PM), occurring in up to 30% of survivors.
236 brospinal fluid from patients with suspected meningitis, presenting to Queen Elizabeth Central Hospit
243 were drafted at an international tuberculous meningitis research meeting organized by the Oxford Univ
246 In this large study of 325 cases of E. coli meningitis, risk factors of severe disease or death were
248 vity had a latitudinal trend, with bacterial meningitis seasons peaking during the winter months in c
249 acteria causes a range of diseases including meningitis, septicaemia, gonorrhoea and endocarditis, an
250 ns were classified as groups 1-3 that caused meningitis, septicemia without meningitis, and septicemi
251 erichia coli K1-mediated neonatal sepsis and meningitis, such as a strong age dependency and developm
255 e variants in a gene region and pneumococcal meningitis susceptibility yielded one significant associ
265 high morbidity and mortality of tuberculous meningitis (TBM), but the link between inflammation and
268 ains that cause urinary tract infections and meningitis, they have not been linked to translocation t
269 tractive treatment strategy for cryptococcal meningitis, though the rising price may be creating acce
270 ree were categorised as probable tuberculous meningitis, three as possible tuberculous meningitis, an
271 eported severity ranges from a self-limiting meningitis to a rapidly fatal meningoencephalitis with m
272 entified the optimal cutoff value for proven meningitis to be 66 pg/ml (sensitivity, 100%; specificit
273 ficity, 94%) and that for probable or proven meningitis to be 66 pg/ml (sensitivity, 91%; specificity
275 BIs), defined as bacteremia and/or bacterial meningitis, using complete blood cell count parameters.
276 the progression and outcome of pneumococcal meningitis, using Kaplan-Meier survival curves, bacterio
277 , PsA-TT (MenAfriVac), developed through the Meningitis Vaccine Project and manufactured by the Serum
283 ortant role in the pathogenesis of bacterial meningitis, we examined whether functional polymorphisms
284 psies from patients who died of pneumococcal meningitis, we observe that pneumococci colocalize with
285 atients with a first episode of cryptococcal meningitis were enrolled, and their immune responses wer
288 sociated with susceptibility to pneumococcal meningitis were rs139064549 on chromosome 1 in the COL11
289 o fever onset within patients with bacterial meningitis when compared with both aseptic and nonmening
290 d treatment is underutilized in pneumococcal meningitis, where it has shown to decrease mortality.
292 d HIV-infected individuals with cryptococcal meningitis who presented to Mulago Hospital in Kampala,
293 lts with a clinical diagnosis of tuberculous meningitis who were admitted to one of two Vietnamese ho
295 s and in 39.3% of patients with pneumococcal meningitis, with an associated decrease in mortality (6.
297 nd 11 from patients with suspected microbial meningitis without fungal diagnosis, for (1,3)-beta-gluc
299 tidis causes 500 000 cases of septicemia and meningitis worldwide annually, with approximately 200 ca
300 throat, scarlet fever, pneumonia, bacterial meningitis, yeast infections, urinary tract infections,
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。